Histopathologic and immunohistochemical prognostic factors in malignant gliomas

Current Opinion in Oncology

Volumn 9, Issue 3, 1997, Pages 230-234

  Stemmer Rachamimov, Anat O ^a   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ASTROCYTOMA; CANCER DIAGNOSIS; CELL PROLIFERATION; ENDOTHELIUM CELL; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0030758108     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709030-00003     Document Type: Short Survey

References (16)

1. Barker FG, Davis RL, Chang SM, Prados MD: Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996. 77:1161-1166. This study addresses the important issue of pathologic diagnosis of GBM in the absence of necrosis and the presence of endothelial proliferation. Multivariate analysts of survival of 275 patients with GBM shows only 2-months survival difference between patients with necrosis-free GBM and patients with necrosis containing GBMs The authors concluded that the diagnosis of GBM on the basis of endothelial proliferation in the absence of necrosis is justified.
2. Leon SP, Folkerth RD, Black PM: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996, 77:362-372. This retrospective multivariate analysis evaluates the correlation between microvessel counts and survival in 95 patients with astrocytic tumors. Microvessel density was found to be an independent prognostic factor of survival.
3. Scott CB, Nelson JS, Farnan NC, Curran WJ, Murray KJ, Fischbach AJ, Gaspar LE, Nelson DF: Central pathology review in clinical trials for patients with malignant glioma. Cancer 1995, 76:307-313 The authors describe the effects of difference in pathologic classification between a central reviewer and the referring institution in a series of 680 patients with astroglial tumors. Seventy-four of the cases were reclassified by the central reviewer and survival curves of each group compared. The study shows the importance of central histologic review in large multicenter trials.
4. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Shinji Y, Masashi T, Kimiyoshi H: Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996, 77:373-380.
5. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psych 1995, 59:413-419. In this large series of 123 astrocytomas, MIB-1 indices and p53 immunohistochemistry were correlated with survival. On multivariate analysis. MIB-1 indices and p53 immunohistochemistry were not found to be independent prognostic indicators.
6. Barker FG, Prados MD, Chang SM, Davis RL, Gutin PH, Lamborn KR, Larson DA, McDermott MW, Sneed PK, Wilson CB: Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival, Int J Radiat Oncol Biol Phys 1996, 34:803-808. Proliferative indices did not provide significant prognostic information in this large series of 200 GBM patients.
7. Karkavelas G, Mavropoulou S, Fountzilas G, Christoforidou V, Karavelis A, Foroglou G, Papadimitriou C: Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res 1995, 15:531-536.
8. Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A: Prognostic factors in low-grade supratentorial astrocytomas: a unimultivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol 1995, 44:208-223.
9. Ono Y, Takashi Y, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 proliferation indices. J Neuropathol Exp Neurol 1996, 55:1026-1031 This study evaluates the correlation between the presence or absence of deletions of the CDKN2/P 76 gene with proliferative indices. Anaplastic astrocytomas and GBMs with CDKN2/p16 deletions share a similar MIB-1 index (20%), and are significantly higher than anaplastic astrocytomas and GBMs without CDKN2/p16 deletions (10%). A molecular approach to assessing tumor biologic behavior is suggested by these results.
10. Heegaard S, Sommer HB, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995, 76:1809-1813. In a series of 32 low-grade oligodendrogliomas, the authors show that high indices of MIB-1 or PCNA labeling are associated with shorter survival. The authors concluded that proliferative indices may be helpful in assessing the biologic behavior of low-grade oligodendrogliomas
11. Kros JM, Hop WCJ, Godschalk JJCJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996, 78:1107-1113. In this large retrospective study of 108 oligodendrogliomas, MIB-1 labeling was shown to be an independent prognostic factor. The results support the use of proliferative indices in assessing oligodendrogliomas.
12. Louis DN, Gusella JF: A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995, 11:412-415.
13. Louis DN: Clinicopatho-genetic subsets of glioblastoma multiforme: from both sides now [editorial]. Brain Pathol 1996, 6:223-224.
14. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, et al.: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial, Clin Neuropathol 1995, 14:169-174.
15. Zhu A, Schaelfer J, Leslie S, Kolm P, Et-Mahdl AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation, Int J Radiat Oncol Biol Phys 1996, 34:809-815.
16. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH: Aberrant p53 expression does not correlate with prognosis in anaplastic astrocytoma. Neurosurg 1995, 37:246-254.